Of these, 7 CRC samples (11.7%) showed IFN-γ release towards PASD1(1) peptide, 1 sample (1.7%) with PASD1(2) peptide and 5 samples (8.3%) with PASD1(3). This evidence concerns the gene IFNG and colorectal carcinoma.